Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In healthy subjects, the incretin effect during an oral glucose tolerance test increases with the size of glucose load, resulting in similar glucose excursions independently of the glucose loads. Whether patients with type 2 diabetes mellitus (T2DM) are able to regulate their incretin effect is unknown. RESEARCH DESIGN AND METHODS: Incretin effect was measured over 6 d by means of three 4-h oral glucose tolerance test with increasing glucose loads (25, 75, and 125 g) and three corresponding isoglycemic iv glucose infusions in eight patients with T2DM [fasting plasma glucose, mean 7.7 (range 7.0-8.9) mM; glycosylated hemoglobin, 7.0% (6.2-8.4%)] and eight matched healthy control subjects [fasting plasma glucose, 5.3 (4.8-5.7) mM; glycosylated hemoglobin, 5.4% (5.0-5.7%)]. RESULTS: Patients with T2DM exhibited higher peak plasma glucose in response to increasing oral glucose loads, whereas no differences in peak plasma glucose values among control subjects were observed. The incretin effect was significantly (P < 0.003) lower in patients with T2DM (0 ± 7, 11 ± 9, and 36 ± 5%) as compared with control subjects (36 ± 5, 53 ± 6, and 65 ± 6%). Equal and progressively delayed gastric emptying due to the increasing loads was found in both groups. Incretin hormone responses were similar. CONCLUSIONS: Up-regulation of the incretin effect in response to increasing oral glucose loads seems to be crucial for controlling glucose excursions in healthy subjects. Patients with T2DM are characterized by an impaired capability to regulate their incretin effect, which may contribute to the exaggerated glucose excursions after oral ingestion of glucose in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [17]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 2×
“The incretin effect is gauged by comparing insulin responses after oral ingestion of glucose and isoglycemic iv glucose infusion (IIGI), respectively (6).”
BackgroundMethodTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 6×
“(7) and us among healthy subjects are likely to result from deceleration of gastric emptying in response to the larger oral glucose loads as indicated by the acetaminophen results of the present study.”
BackgroundResultInfluentialDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Research works printed but not linked: 3
- Willms, 1994, Inhibition of gastric emptying by glucagon-like peptide (7-36) amide in patients with type-2 diabetes mellitus., Diabetologia, 37, A118
- Knop, 2009, Glucagon responses to increasing oral loads of glucose and corresponding isoglycemic intravenous glucose infusions in patients with type 2 diabetes and healthy subjects., Diabetes, 58, A368
- Knop, 2008, Redcuced incretin effect in obese subjects with normal glucose tolerance as compared to lean control subjects., Diabetes, 57, A410
Cited by
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“As the consequence of the dose-dependent secretion and insulinotropic action of the incretin hormones GIP and GLP-1, widely different oral glucose loads lead to an almost uniform plasma glucose concentration profile.(38,39) The explanation is the variation in the quantitative contribution of the incretin effect to the…”
BackgroundSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
“In addition, pharmacological manipulation of gastric emptying of a solid-liquid mixed-nutrient meal produced corresponding glycemic changes in patients with T2DM (285).”
BackgroundInfluentialNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Impact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationβ Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
Yabe, D., Seino, Y., Fukushima, M., & Seino, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0602-9 · Cited by 328
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Obesity and diabetes: An update
Verma, S., & Hussain, M. E. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.06.017 · Cited by 318
Nannipieri, M., Baldi, S., Mari, A., Colligiani, D., Guarino, D., Camastra, S., Barsotti, E., Berta, R., Moriconi, D., Bellini, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2538 · Cited by 293
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
“More recently, reduced GLP-1 responses have also been observed after OGTTs in mainly male, severely obese (BMI >35 kg/m2) patients with type 2 diabetes [23, 31].”
InfluentialSelf-citationThe incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
“Subsequent studies showed that the secretion of the incretin hormones followed the same pattern in healthy control participants and in people with type 2 diabetes, supporting the comparatively greater stimulation of insulin secretion with ingested glucose [39].”
ResultSelf-citationMakrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
Roles of the Gut in Glucose Homeostasis
Holst, J. J., Gribble, F., Horowitz, M., & Rayner, C. K. (2016) · Diabetes Care · doi:10.2337/dc16-0351 · Cited by 205
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“Data from (a, g) Nauck et al [2] (oral glucose load 50 g); (b, h) Knop et al [71] (oral glucose load 75 g); (c, i) Bagger et al [3] (oral glucose loads of 25, 75 and 125 g); (d, j) Vardarli et al [72] (oral glucose load 75 g; after placebo and vildagliptin treatment); (e, k) Vardarli et al 2014 [73] (oral glucose load…”
BackgroundMethodGlucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Wu, T., Zhao, B. R., Bound, M. J., Checklin, H. L., Bellon, M., Little, T. J., Young, R. L., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.021543 · Cited by 163
“In patients with type 2 diabetes, the incretin effect is impaired (4).”
BackgroundSecretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158
“Subgroup one included trials with participants with mean HbA1c #7% (53 mmol/mol) (6,11,17,20, 21,24,26); subgroup two included trials with mean HbA1c .”
BackgroundSelf-citationComparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
“Diminished capability to up-regulate incretin effect in response to increasing oral glucose loads([9]) and impaired islet responses to GIP and GLP-1 with progressive, ultimately total loss of incretin effect are fundamental metabolic defects found in most, if not all patients with type 2 diabetes mellitus.”
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
Regulation of glucagon secretion by incretins
Holst, J. J., Christensen, M., Lund, A., de Heer, J., Svendsen, B., Kielgast, U., & Knop, F. K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01452.x · Cited by 144
Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
“Incretins are secreted by endocrine cells of the intestinal epithelium in a dose-response relationship with the intestinal glucose load.(19) Beta”
BackgroundPhysiology of Incretins in Health and Disease
Deacon, C. F., & Ahrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 126
The Role of Incretins on Insulin Function and Glucose Homeostasis
Holst, J. J., Gasbjerg, L. S., & Rosenkilde, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab065 · Cited by 124
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationInflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study
Jess, T., Jensen, B. W., Andersson, M., Villumsen, M., & Allin, K. H. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.052 · Cited by 112
Bernsmeier, C., Meyer-Gerspach, A. C., Blaser, L. S., Jeker, L., Steinert, R. E., Heim, M. H., & Beglinger, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087488 · Cited by 109
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
Junker, A. E., Gluud, L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12462 · Cited by 88
Lee, J., Cummings, B. P., Martin, E., Sharp, J. W., Graham, J. L., Stanhope, K. L., Havel, P. J., & Raybould, H. E. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00345.2011 · Cited by 84
Shadid, S., Abosi-Appeadu, K., De Maertelaere, A.-S., Defreyne, J., Veldeman, L., Holst, J. J., Lapauw, B., Vilsbøll, T., & T’Sjoen, G. (2020) · Diabetes Care · doi:10.2337/dc19-1061 · Cited by 82
Tissue Renin–Angiotensin Systems: A Unifying Hypothesis of Metabolic Disease
Skov, J., Persson, F., Frøkiær, J., & Christiansen, J. S. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00023 · Cited by 91
Ma, J., Pilichiewicz, A. N., Feinle‐Bisset, C., Wishart, J. M., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03496.x · Cited by 82
Incretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 80
Zhang, C., Ma, S., Wu, J., Luo, L., Qiao, S., Li, R., Xu, W., Wang, N., Zhao, B., Wang, X. D., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104985 · Cited by 79
Yabe, D., Kuroe, A., Watanabe, K., Iwasaki, M., Hamasaki, A., Hamamoto, Y., Harada, N., Yamane, S., Lee, S., Murotani, K., et al. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.010 · Cited by 69
GIP and GLP-1 receptor antagonism during a meal in healthy individuals
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz175 · Cited by 68
Self-citationBagger, J. I., Knop, F. K., Lund, A., Holst, J. J., & Vilsbøll, T. (2014) · Diabetologia · doi:10.1007/s00125-014-3264-2 · Cited by 77
GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family
Nauck, M. A., & Meier, J. J. (2019) · Diabetes · doi:10.2337/dbi19-0005 · Cited by 65
Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
Ahrén, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64
Sottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 84
Combining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Holst, J. J., & Vilsbøll, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01628.x · Cited by 63
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“Here, it is important to mention that studies that also include NW/NGT individuals [47,50] can provide a more comprehensive picture of GLP-1 secretion, and possible step-wise alterations, across different metabolic stages than the studies that only compare OW and T2DM [53].”
BackgroundResultInfluentialSelf-citationQiu, S., Bosnyák, E., Treff, G., Steinacker, J. M., Niess, A. M., Krüger, K., Mooren, F. C., Zügel, M., & Schümann, U. (2018) · European Journal of Sport Science · doi:10.1080/17461391.2018.1478452 · Cited by 69
Seimon, R. V., Brennan, I. M., Russo, A., Little, T. J., Jones, K. L., Standfield, S., Wishart, J. M., Horowitz, M., & Feinle-Bisset, C. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00533.2012 · Cited by 60
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Knop, F. K., Vilsbøll, T., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0264 · Cited by 58
Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes
Kimple, M. E., Neuman, J. C., Linnemann, A. K., & Casey, P. J. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.40 · Cited by 55
Bariatric surgery and obesity: influence on the incretins
Laferrère, B. (2016) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2016.8 · Cited by 58
Kizilkaya, H. S., Sørensen, K. V., Madsen, J. S., Lindquist, P., Douros, J. D., Bork‐Jensen, J., Berghella, A., Gerlach, P. A., Gasbjerg, L. S., Mokrosiński, J., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01061-4 · Cited by 63
Hoefle, A. S., Bangert, A., Stamfort, A., Gedrich, K., Rist, M. J., Lee, Y., Skurk, T., & Daniel, H. (2015) · Journal of Nutrition · doi:10.3945/jn.114.199190 · Cited by 57
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Marathe, C. S., Rayner, C. K., Bound, M., Checklin, H., Standfield, S., Wishart, J., Lange, K., Jones, K. L., & Horowitz, M. (2014) · Diabetes · doi:10.2337/db13-1757 · Cited by 53
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Knop, F. K., Hansen, K. B., & Knop, F. K. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7004 · Cited by 64
EJE PRIZE 2018: A gut feeling about glucagon
Knop, F. K. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0197 · Cited by 47
Self-citationPortron, A., Jadidi, S., Sarkar, N., DiMarchi, R., & Schmitt, C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13025 · Cited by 46
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 45
COHEN, R. V., Caravatto, P. P. D. P., Correa, J. L., Noujaim, P. M., Petry, T. B. Z., Salles, J. E. N., & Schiavon, C. A. (2012) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2012.01.017 · Cited by 51
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 49
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Cancers · doi:10.3390/cancers14194651 · Cited by 63
Ichikawa, R., Takano, K., Fujimoto, K., Motomiya, T., Kobayashi, M., Kitamura, T., & Shichiri, M. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0372 · Cited by 43
Manell, E., Hedenqvist, P., Svensson, A. C., & Jensen‐Waern, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148896 · Cited by 51
Petrovic, A., Igrec, D., Rozac, K., Bojanic, K., Kuna, L., Kolaric, T. O., Mihaljevic, V., Sikora, R., Smolic, R., Glasnovic, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060288 · Cited by 41
Pinelli, N., Berlie, & Hurren (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s27528 · Cited by 41
Mari, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073154 · Cited by 40
The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes
Oh, T. J., Kim, M. Y., Shin, J. Y., Lee, J. C., Kim, S., Park, K. S., & Cho, Y. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12167 · Cited by 40
Yamane, S., Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., et al. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00143.x · Cited by 42
Cheng, Y.-H., Ho, M.-S., Huang, W.-T., Chou, Y.-T., & King, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655662 · Cited by 38
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
Martínez, M. S., Manzano, A., Olivar, L. C., Nava, M., Salazar, J. J., D’Marco, L., Ortíz, R., Chacín, M., Guerrero‐Wyss, M., de Bravo, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179504 · Cited by 42
Guo, X.-H. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 33
Kokkorakis, M., Katsarou, A., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155689 · Cited by 34
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Rojano‐Toimil, A., & Ciudin, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173955 · Cited by 38
Hamad, S., Zafar, T. A., & Sidhu, J. S. (2017) · Nutrition · doi:10.1016/j.nut.2017.09.010 · Cited by 39
Fatima, F., Hjelmesaeth, J. S., Birkeland, K. I., Gulseth, H. L., Hertel, J. K., Svanevik, M., Sandbu, R., Småstuen, M. C., Hartmann, B., Holst, J. J., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab643 · Cited by 39
Idorn, T., Knop, F. K., Jørgensen, M. B., Holst, J. J., Hornum, M., & Feldt‐Rasmussen, B. (2013) · Kidney International · doi:10.1038/ki.2012.460 · Cited by 34
Demant, M., Bagger, J. I., Suppli, M. P., Lund, A., Gyldenløve, M., Hansen, K. B., Hare, K. J., Christensen, M., Sonne, D. P., Holst, J. J., et al. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0066 · Cited by 38
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
Repositioning the Alpha Cell in Postprandial Metabolism
EL, K. M., Capozzi, M. E., & Campbell, J. E. (2020) · Endocrinology · doi:10.1210/endocr/bqaa169 · Cited by 37
Zhang, J., Zheng, Y., Martens, L., & Pfeiffer, A. F. H. (2023) · Nutrients · doi:10.3390/nu15183913 · Cited by 40
Vedtofte, L., Bahne, E., Foghsgaard, S., Bagger, J. I., Andreasen, C., Strandberg, C., Gørtz, P. M., Holst, J. J., Grønbæk, H., Svare, J. A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103213 · Cited by 29
Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
Nisal, K., Kela, R., Khunti, K., & Davies, M. J. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-152 · Cited by 33
Seino, Y., Takami, A., Boka, G., Niemoeller, E., Raccah, D., & on behalf of the PDY6797 investigators (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12276 · Cited by 28
The power of three: Retatrutide’s role in modern obesity and diabetes therapy
Abdul-Rahman, T., Roy, P., Ahmed, F. K., Mueller-Gomez, J. L., Sarkar, S., Garg, N., Femi-Lawal, V. O., Wireko, A. A., Thaalibi, H. I., Hashmi, M. U., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177095 · Cited by 27
Alsalim, W., Lindgren, O., & Åhrén, B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13962 · Cited by 30
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Montanya, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.692777 · Cited by 27
Grespan, E., Giorgino, T., Natali, A., Ferrannini, E., & Mari, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154415 · Cited by 27
Foghsgaard, S., Vedtofte, L., Andersen, E. S., Bahne, E., Andreasen, C. H., Sørensen, A. L., Forman, J. L., Mathiesen, E. R., Svare, J., Clausen, T. D., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15306 · Cited by 28
Wang, X., Ye, F., Li, J., Zhu, L., Feng, G. L., Chang, X., & Sun, K. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.1.12035 · Cited by 27
The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
Aulinger, B. A., Vahl, T. P., Prigeon, R. L., D'Alessio, D. A., & Elder, D. A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00496.2015 · Cited by 24
Metadata
- Authors
- Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T.
- Affiliations
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
- University of Copenhagen (DK)
- Corresponding author
- Vilsbøll, Tina
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-03-01
- Volume
- 96
- Issue
- 3
- Pages
- 737-745
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2041551639
- Cited by
- 219
- References
- 33
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 14 · 2023: 15 · 2022: 8 · 2021: 14 · 2020: 15 · 2019: 18 · 2018: 11 · 2017: 14 · 2016: 25 · 2015: 17 · 2014: 14 · 2013: 23 · 2012: 10
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- incretin effect, type 2 diabetes, oral glucose tolerance test, glucose load, glycemic excursions, gastric emptying, glucose homeostasis
- MeSH terms
- Insulin Secretion, Acetaminophen, Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Analgesics, Non-Narcotic, Area Under Curve, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.